|
1
|
Sionov RV and Haupt Y: The cellular
response to p53: The decision between life and death. Oncogene.
18:6145–6157. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vousden KH and Lu X: Live or let die: The
cell's response to p53. Nat Rev Cancer. 2:594–604. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Levine AJ: The tumor suppressor genes.
Annu Rev Biochem. 62:623–651. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moll UM and Petrenko O: The MDM2-p53
interaction. Mol Cancer Res. 1:1001–1008. 2003.PubMed/NCBI
|
|
5
|
Linares LK, Hengstermann A, Ciechanover A,
Müller S and Scheffner M: HdmX stimulates Hdm2-mediated
ubiquitination and degradation of p53. Proc Natl Acad Sci USA.
100:12009–12014. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shvarts A, Steegenga WT, Riteco N, van
Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt
W, Hateboer G, van der Eb AJ and Jochemsen AG: MDMX: A novel
p53-binding protein with some functional properties of MDM2. EMBO
J. 15:5349–5357. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu X, Bayle JH, Olson D and Levine AJ: The
p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126–1132.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahmoodi Chalbatani G, Dana H,
Gharagouzloo E, Grijalvo S, Eritja R, Logsdon CD, Memari F, Miri
SR, Rad MR and Marmari V: Small interfering RNAs (siRNAs) in cancer
therapy: A nano-based approach. Int J Nanomedicine. 14:3111–3128.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Imanishi M, Yamamoto Y, Wang X, Sugaya A,
Hirose M, Endo S, Natori Y, Yamato K and Hyodo I: Augmented
antitumor activity of 5-fluorouracil by double knockdown of MDM4
and MDM2 in colon and gastric cancer cells. Cancer Sci.
110:639–649. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hirose M, Yamato K, Endo S, Saito R, Ueno
T, Hirai S, Suzuki H, Abei M, Natori Y and Hyodo I: MDM4 expression
as an indicator of TP53 reactivation by combined targeting of MDM2
and MDM4 in cancer cells without TP53 mutation. Oncoscience.
1:830–843. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Endo S, Yamato K, Hirai S, Moriwaki T,
Fukuda K, Suzuki H, Abei M, Nakagawa I and Hyodo I: Potent in vitro
and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric
cancer cells. Cancer Sci. 102:605–613. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Malmlöf M, Roudier E, Högberg J and
Stenius U: MEK-ERK-mediated phosphorylation of Mdm2 at Ser-166 in
hepatocytes. Mdm2 is activated in response to inhibited Akt
signaling. J Biol Chem. 282:2288–2296. 2007. View Article : Google Scholar
|
|
13
|
Ries S, Biederer C, Woods D, Shifman O,
Shirasawa S, Sasazuki T, McMahon M, Oren M and McCormick F:
Opposing effects of Ras on p53: Transcriptional activation of mdm2
and induction of p19ARF. Cell. 103:321–330. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hata AN, Rowley S, Archibald HL,
Gomez-Caraballo M, Siddiqui FM, Ji F, Jung J, Light M, Lee JS,
Debussche L, et al: Synergistic activity and heterogeneous acquired
resistance of combined MDM2 and MEK inhibition in KRAS mutant
cancers. Oncogene. 36:6581–6591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bronkhorst AJ, Wentzel JF, Aucamp J, van
Dyk E, du Plessis L and Pretorius PJ: Characterization of the
cell-free DNA released by cultured cancer cells. Biochim Biophys
Acta. 1863:157–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsujimoto Y and Croce CM: Analysis of the
structure, transcripts, and protein products of bcl-2, the gene
involved in human follicular lymphoma. Proc Natl Acad Sci USA.
83:5214–5218. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: Release of cytochrome c from mitochondria blocked. Science.
275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reshi L, Wang HV, Hui CF, Su YC and Hong
JR: Anti-apoptotic genes Bcl-2 and Bcl-xL overexpression can block
iridovirus serine/threonine kinase-induced
Bax/mitochondria-mediated cell death in GF-1 cells. Fish Shellfish
Immunol. 61:120–129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rodríguez J, Calvo F, González JM, Casar
B, Andrés V and Crespo P: ERK1/2 MAP kinases promote cell cycle
entry by rapid, kinase-independent disruption of
retinoblastoma-lamin A complexes. J Cell Biol. 191:967–979. 2010.
View Article : Google Scholar
|
|
21
|
Bidère N and Senik A: Caspase-independent
apoptotic pathways in T lymphocytes: A minireview. Apoptosis.
6:371–375. 2001. View Article : Google Scholar
|
|
22
|
Wu M, Xu LG, Li X, Zhai Z and Shu HB:
AMID, an apoptosis-inducing factor-homologous
mitochondrion-associated protein, induces caspase-independent
apoptosis. J Biol Chem. 277:25617–25623. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee TJ, Kim EJ, Kim S, Jung EM, Park JW,
Jeong SH, Park SE, Yoo YH and Kwon TK: Caspase-dependent and
caspase-independent apoptosis induced by evodiamine in human
leukemic U937 cells. Mol Cancer Ther. 5:2398–2407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mandal R, Raab M, Matthess Y, Becker S,
Knecht R and Strebhardt K: pERK 1/2 inhibit caspase-8 induced
apoptosis in cancer cells by phosphorylating it in a cell cycle
specific manner. Mol Oncol. 8:232–249. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Allan LA, Morrice N, Brady S, Magee G,
Pathak S and Clarke PR: Inhibition of caspase-9 through
phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol. 5:647–654.
2003. View Article : Google Scholar : PubMed/NCBI
|
